| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/12/2009 | US7531533 6-Membered heterocyclic compound and use thereof |
| 05/12/2009 | US7531532 Pyridine derivative and pyrimidine derivative |
| 05/12/2009 | US7531531 Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles |
| 05/12/2009 | US7531530 derivatives of tricyclic lactam indoles and tricyclic lactam benzimidazoles; poly (ADP-ribose) polymerase (PARP) inhibitors; breast cancer, cancers caused by genetic defect in a gene; side effects reduction by not administering as a combination therapy; low doses; antiapoptosis; BRCA1 or BRCA2 expression |
| 05/12/2009 | US7531529 Metabotropic glutamate (mGluR5) receptor mediated disorders; genitourinary diseases; containing pyridin-4-ylethynyl functionality |
| 05/12/2009 | US7531528 mixture of aqueous carrier liquid containing dissolved glucocorticoid and 3-oxoandrostane carbothioic coompound |
| 05/12/2009 | US7531527 (20R)-1 alpha ,25-dihydroxy-2-[3'-hydroxypropylidene]-19-norvitamin D3; high intestinal calcium transport activity; ability to mobilize calcium from bone; bone replacement surgeries, autoimmune diseases, multiple sclerosis, diabetes mellitus,lupus, antiproliferative agents |
| 05/12/2009 | US7531526 Boronic ester and acid compounds, synthesis and uses |
| 05/12/2009 | US7531525 Administering the salt, which is a P2Y purinergic receptor agonist that is hydrolysis-resistant to stimulate the removal of pathological fluid accumulation |
| 05/12/2009 | US7531521 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 05/12/2009 | US7531519 inhibiting norepinephrine reuptake; inhibits the [125I]RTI-55 binding to norepinephrine transporter protein; water soluble plant extract from Polygala tenuifolia |
| 05/12/2009 | US7531514 Orally administered peptides synergize statin activity |
| 05/12/2009 | US7531503 Cell scaffold matrices with incorporated therapeutic agents |
| 05/12/2009 | US7531501 Method of treating endothelial injury |
| 05/12/2009 | US7531500 Preventing airway mucus production by administration of EGF-R antagonists |
| 05/12/2009 | US7531499 Spermine to facilitate absorption of cilostazol, rebamipide, cyclosporin and nifedipine |
| 05/12/2009 | US7531347 Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
| 05/12/2009 | US7531320 Modulation of β-catenin/TCF-activated transcription |
| 05/12/2009 | US7531175 Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules |
| 05/12/2009 | US7531162 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation |
| 05/12/2009 | US7531148 Oxidation reactor |
| 05/12/2009 | US7530461 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 05/12/2009 | CA2611659A1 Method for enhancing delivery and uniformity of concentration of dietary ingredients |
| 05/12/2009 | CA2548078C Pharmaceutical formulations of camptothecins and process for making same |
| 05/12/2009 | CA2546987C 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity |
| 05/12/2009 | CA2518102C Powdery preparation for nasal administration |
| 05/12/2009 | CA2517933C Novel fused heteroaromatic compounds as transforming growth factor (tgf) inhibitors |
| 05/12/2009 | CA2492526C Method for controlling hairballs |
| 05/12/2009 | CA2484494C High dose ibandronate formulation |
| 05/12/2009 | CA2478237C Use of adapalene for the treatment of dermatological disorders |
| 05/12/2009 | CA2475302C Controlled synthesis of ziprasidone and compositions thereof |
| 05/12/2009 | CA2437785C Hiv inhibiting pyrazinone derivatives |
| 05/12/2009 | CA2419178C Cytokine production inhibitor |
| 05/12/2009 | CA2412561C Highly efficient delivery of a large therapeutic mass aerosol |
| 05/12/2009 | CA2402742C Method of treating or inhibiting colonic polyps |
| 05/12/2009 | CA2395458C Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
| 05/12/2009 | CA2389156C Benzamidine derivatives |
| 05/12/2009 | CA2387398C Novel combination of loteprednol and antihistamines |
| 05/12/2009 | CA2386817C The use of baclofen in the treatment of alcoholism |
| 05/12/2009 | CA2386404C Method of treating inflammatory conditions with progesterone or progesterone analogs |
| 05/12/2009 | CA2377301C Controlled release and taste masking oral pharmaceutical compositions |
| 05/12/2009 | CA2377299C Mesalazine controlled release oral pharmaceutical compositions |
| 05/12/2009 | CA2361402C Bis-sulfonamides |
| 05/12/2009 | CA2356080C Improved formulation for transportation of corticosteroid through pores of a barrier |
| 05/12/2009 | CA2348890C Use of staurosporine derivatives for treating ocular neovascular diseases |
| 05/12/2009 | CA2341973C Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid |
| 05/12/2009 | CA2341891C The use of r(+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
| 05/12/2009 | CA2335353C Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ards) and infant respiratory distress syndrome (irds) |
| 05/12/2009 | CA2334875C Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome |
| 05/12/2009 | CA2324921C Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections |
| 05/12/2009 | CA2322027C Use of macrolide compounds for the treatment of ards |
| 05/12/2009 | CA2315829C Angiostatic agents and compositions for controlling ocular hypertension |
| 05/12/2009 | CA2303448C Specific steady-state r-type ca2+ channel blockers and use thereof |
| 05/12/2009 | CA2295616C Use of phosphodiesterase inhibitors in the treatment of prostatic diseases |
| 05/12/2009 | CA2284079C Immunotoxins and methods of inducing immune tolerance |
| 05/12/2009 | CA2264005C Piperazino derivatives as neurokinin antagonists |
| 05/12/2009 | CA2253997C Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| 05/12/2009 | CA2228266C Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 05/12/2009 | CA2213254C Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
| 05/12/2009 | CA2136492C Pharmaceutical composition containing diclofenac and 2-hydroxypropyl-.beta.-cyclodextrin |
| 05/11/2009 | CA2705453A1 Pharmaceutical compositions |
| 05/09/2009 | CA2643622A1 New crystalline form vi of agometaline, the process for making it and pharmaceutical compositions containing it |
| 05/07/2009 | WO2009059283A1 Non-anticoagulant polysaccharide compositions |
| 05/07/2009 | WO2009059272A1 Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| 05/07/2009 | WO2009059260A1 Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse |
| 05/07/2009 | WO2009059239A2 REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| 05/07/2009 | WO2009059214A1 Abeta-binding small molecules |
| 05/07/2009 | WO2009059208A1 Compositions and methods for treating cancer |
| 05/07/2009 | WO2009059191A1 Compositions and methods for treatment of ear canal infection and inflammation |
| 05/07/2009 | WO2009059188A1 Method of treating vitamin b12 deficiency |
| 05/07/2009 | WO2009059162A1 Cytokine inhibitors |
| 05/07/2009 | WO2009059121A1 Methods of augmenting or repairing soft tissue |
| 05/07/2009 | WO2009059077A1 Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function |
| 05/07/2009 | WO2009059050A2 Tlr modulators and methods for using the same |
| 05/07/2009 | WO2009059048A2 (+)-opioids and methods of use |
| 05/07/2009 | WO2009058958A2 Lipoxin a4 protection for cornea endothelial cells |
| 05/07/2009 | WO2009058945A1 Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer |
| 05/07/2009 | WO2009058924A1 Ccr5 antagonists as therapeutic agents |
| 05/07/2009 | WO2009058923A1 Ccr5 antagonists as therapeutic agents |
| 05/07/2009 | WO2009058921A1 Ccr5 antagonists as therapeutic agents |
| 05/07/2009 | WO2009058919A1 Ccr5 antagonists as therapeutic agents |
| 05/07/2009 | WO2009058907A2 Targeting micrornas for the treatment of liver cancer |
| 05/07/2009 | WO2009058898A2 Method and apparatus for diagnoses of hemangiosarcoma in mammals |
| 05/07/2009 | WO2009058874A1 Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase |
| 05/07/2009 | WO2009058859A2 Dispiro 1,2,4-trioxolane antimalarials |
| 05/07/2009 | WO2009058848A2 Methods and devices for testing germicide activity |
| 05/07/2009 | WO2009058815A2 Lipoxin a4 protection for retinal cells |
| 05/07/2009 | WO2009058801A1 Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer |
| 05/07/2009 | WO2009058739A1 Heterocyclic urea and thiourea derivatives and methods of use thereof |
| 05/07/2009 | WO2009058730A1 Diamido thiazole derivatives as protein kinase inhibitors |
| 05/07/2009 | WO2009058728A1 Thiazole derivatives as protein kinase inhibitors |
| 05/07/2009 | WO2009058653A1 Amino-heteroaryl-containing prokineticin 1 receptor antagonists |
| 05/07/2009 | WO2009058613A1 Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
| 05/07/2009 | WO2009058585A2 Non-aqueous water-miscible materials as vehicles for drug delivery |
| 05/07/2009 | WO2009058552A1 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| 05/07/2009 | WO2009058493A1 Prostaglandin analog compositions and methods to treat epithelial-related conditions |
| 05/07/2009 | WO2009058403A1 Methods for reducing blood pressure |
| 05/07/2009 | WO2009058394A1 Cytidine analogs for treatment of myelodysplastic syndromes |
| 05/07/2009 | WO2009058361A1 Inhibition of type i ifn production |
| 05/07/2009 | WO2009058348A1 Amide derivatives as sirtuin modulators |